Navaneethakrishnan Krishnamoorthy

Dr. Navaneethakrishnan Krishnamoorthy

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2008 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
YKYs Kang
Ys Kang
SPSy Park
Sy Park
CYCh Yim
Ch Yim
HKHs Kwak
Hs Kwak
PGP Gajendrarao
P Gajendrarao
KHKo Han
Ko Han

22 March 2021 in IUBMB Life
Verified
Journal Article
Open access
PDF file
NKNavaneethakrishnan Krishnamoorthy
Navaneethakrishnan Krishnamoorthy
KFKhalid A. Fakhro
Khalid A. Fakhro
Mutations in the novel coronavirus SARS‐CoV2 are the major concern as they might lead to drug/vaccine resistance. In the host cell, the virus largely depends on the main protease (Mpro) to regulate infection hence it is one of the most attractive targets for inhibitor design. However, >19,000 mutations in the Mpro have already been reported. The mutations encompassing 282 amino acid positions and these “hotspots” might change the Mpro structure, activity and potentially delay therapeutic strategies targeting Mpro. Thus, here we identified 24 mutational “coldspots” where mutations have not been observed. We compared the structure–function relationship of these coldspots with several SARS‐CoV2 Mpro X‐ray crystal structures. We found that three coldspot residues (Leu141, Phe185, and Gln192) help to form the active site, while seven (Gly2, Arg4, Tyr126, Lys137, Leu141, Leu286, and Leu287) contribute to dimer formation that is required for Mpro activity. The surface of the dimer interface is more resistant to mutations compared to the active site. Interestingly, most of the coldspots are found in three clusters and forms conserved patterns when compared with other coronaviruses. Importantly, several conserved coldspots are available on the surface of the active site and at the dimer interface for targeting. The identification and short list of these coldspots offers a new perspective to target the SARS‐CoV2 Mpro while avoiding mutation‐based drug resistance.

1 October 2011 in Biomaterials
Verified
Journal Article
Closed access
NKNavaneethakrishnan Krishnamoorthy
Navaneethakrishnan Krishnamoorthy
MYMagdi H. Yacoub
Magdi H. Yacoub
SYSophia N. Yaliraki
Sophia N. Yaliraki

17 August 2016 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
OZOsama K Zaki
Osama K Zaki
NKNavaneethakrishnan Krishnamoorthy
Navaneethakrishnan Krishnamoorthy
HAHeba S El Abd
Heba S El Abd
SHSoumaya A Harche
Soumaya A Harche
RMReem A Mattar
Reem A Mattar
HZHatem Zayed
Hatem Zayed

1 August 2017 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
MAMoza K. Alkowari
Moza K. Alkowari
DVDiego Vozzi
Diego Vozzi
SBShruti Bhagat
Shruti Bhagat
NKNavaneethakrishnan Krishnamoorthy
Navaneethakrishnan Krishnamoorthy
AMAnna Morgan
Anna Morgan
KAKhalid Abdulhadi
Khalid Abdulhadi

29 August 2009 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
NKNavaneethakrishnan Krishnamoorthy
Navaneethakrishnan Krishnamoorthy
PGPoornima Gajendrarao
Poornima Gajendrarao
STSundarapandian Thangapandian
Sundarapandian Thangapandian
YLYuno Lee
Yuno Lee
KLKeun Woo Lee
Keun Woo Lee